- 作者：Marissa Howard-McNatt ; M.D.a ; mmcnatt@wakehealth.edu ; Julia Lawrence ; M.D.b ; Susan A. Melin ; M.D.b ; Edward A. Levine ; M.D.a ; Perry Shen ; M.D.a ; John H. Stewart IV ; M.D.a
- 关键词：Neoadjuvant chemotherapy ; Breast cancer ; Race
- 刊名：The American Journal of Surgery
- 出版年：2013
- 出版时间：April, 2013
- 年：2013
- 卷：205
- 期：4
- 页码：397-401
- 全文大小：296 K
class=""h4"">Background
Black women can have worse outcomes than white women with breast cancer. We examined survival in black and white women who received neoadjuvant chemotherapy.class=""h4"">Methods
We identified 98 women with stage II or III breast cancer who underwent neoadjuvant chemotherapy. Women with inflammatory breast cancer, T4 disease, or metastases were excluded. Data were analyzed using the Fisher exact test and Kaplan-Meier method.
class=""h4"">Results
From the cohort, 69 women were included. The median follow-up was 6.2 years. The estrogen receptor status was similar. White women tended to overexpress human epidermal growth factor receptor 2 (HER2) (P = .091). The pretreatment T stage was T3. All women received similar neoadjuvant chemotherapy. The 5-year progression-free survival was better for white women compared with black women (78 % vs 58 % , P?= .05). The 5-year overall survival was similar (P = .095).
class=""h4"">Conclusions
The pretreatment characteristics of women receiving neoadjuvant chemotherapy were similar. Black women had a worse disease-free survival. The overall survival was the same.